Habermann TM - Search Results

1

Randomized Phase III Trial Comparing ABVD Plus Radiotherapy With the Stanford V Regimen in Patients With Stages I or II Locally Extensive, Bulky Mediastinal Hodgkin Lymphoma: A Subset Analysis of the North American Intergroup E2496 Trial.

Advani RH, Hong F, Fisher RI, Bartlett NL, Robinson KS, Gascoyne RD, Wagner H Jr, Stiff PJ, Cheson BD, Stewart DA, Gordon LI, Kahl BS, Friedberg JW, Blum KA, Habermann TM, Tuscano JM, Hoppe RT, Horning SJ. Advani RH, et al. Among authors: habermann tm. J Clin Oncol. 2015 Jun 10;33(17):1936-42. doi: 10.1200/JCO.2014.57.8138. Epub 2015 Apr 20. J Clin Oncol. 2015. PMID: 25897153 Free PMC article. Clinical Trial.

2

Randomized comparison of pentostatin versus interferon alfa-2a in previously untreated patients with hairy cell leukemia: an intergroup study.

Grever M, Kopecky K, Foucar MK, Head D, Bennett JM, Hutchison RE, Corbett WE, Cassileth PA, Habermann T, Golomb H, et al. Grever M, et al. J Clin Oncol. 1995 Apr;13(4):974-82. doi: 10.1200/JCO.1995.13.4.974. J Clin Oncol. 1995. PMID: 7707126 Clinical Trial.

3

Treatment of stage IE primary lymphoma of bone.

Fairbanks RK, Bonner JA, Inwards CY, Strickler JG, Habermann TM, Unni KK, Su J. Fairbanks RK, et al. Among authors: habermann tm. Int J Radiat Oncol Biol Phys. 1994 Jan 15;28(2):363-72. doi: 10.1016/0360-3016(94)90059-0. Int J Radiat Oncol Biol Phys. 1994. PMID: 8276651

4

Phase I trial of dose escalation with growth factor support in patients with previously untreated diffuse aggressive lymphomas: determination of the maximum-tolerated dose of ProMACE-CytaBOM.

Gordon LI, Anderson J, Habermann TM, Winter JN, Glick J, Schilder RJ, Cassileth P. Gordon LI, et al. Among authors: habermann tm. J Clin Oncol. 1996 Apr;14(4):1275-81. doi: 10.1200/JCO.1996.14.4.1275. J Clin Oncol. 1996. PMID: 8648384 Clinical Trial.

5

Predictive capacity of the International Prognostic Factor Index in patients with peripheral T-cell lymphoma.

Ansell SM, Habermann TM, Kurtin PJ, Witzig TE, Chen MG, Li CY, Inwards DJ, Colgan JP. Ansell SM, et al. Among authors: habermann tm. J Clin Oncol. 1997 Jun;15(6):2296-301. doi: 10.1200/JCO.1997.15.6.2296. J Clin Oncol. 1997. PMID: 9196143

6

Primary pulmonary lymphoma.

Habermann TM, Ryu JH, Inwards DJ, Kurtin PJ. Habermann TM, et al. Semin Oncol. 1999 Jun;26(3):307-15. Semin Oncol. 1999. PMID: 10375087 Review.

7

Primary thyroid lymphoma.

Ansell SM, Grant CS, Habermann TM. Ansell SM, et al. Among authors: habermann tm. Semin Oncol. 1999 Jun;26(3):316-23. Semin Oncol. 1999. PMID: 10375088 Review.

8

A phase II trial of 200% ProMACE-CytaBOM in patients with previously untreated aggressive lymphomas: analysis of response, toxicity, and dose intensity.

Gordon LI, Young M, Weller E, Habermann TM, Winter JN, Glick J, Ghosh C, Flynn P, Cassileth PA. Gordon LI, et al. Among authors: habermann tm. Blood. 1999 Nov 15;94(10):3307-14. Blood. 1999. PMID: 10552939 Free article. Clinical Trial.

9

Non-Hodgkin's lymphoma: present status and future prospects.

Habermann TM. Habermann TM. Hosp Pract (1995). 1999 Dec 15;34(13):81-4, 87-8. doi: 10.3810/hp.1999.12.178. Hosp Pract (1995). 1999. PMID: 10611900

10

Phase II trail of didemnin B in previously treated non-Hodgkin's lymphoma: an Eastern Cooperative Oncology Group (ECOG) Study.

Kucuk O, Young ML, Habermann TM, Wolf BC, Jimeno J, Cassileth PA. Kucuk O, et al. Among authors: habermann tm. Am J Clin Oncol. 2000 Jun;23(3):273-7. doi: 10.1097/00000421-200006000-00013. Am J Clin Oncol. 2000. PMID: 10857892 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

469 results

Search Page

Filters